Product Information
TRICITRATES ORAL SOLUTION is a generic product labeled by PAI Holdings LLC, priced at $0.0314 per ML under NDC 00121067716. Its NADAC has been published 423 times since Nov 28, 2013.
TRICITRATES ORAL SOLUTION
POTASSIUM CITRATE, SODIUM CITRATE, and CITRIC ACID MONOHYDRATEStrength
334; 550; 500 mg/5mL; mg/5mL; mg/5mL
Manufacturer
PAI Holdings LLCNDC
00121067716
Classification
Generic
Dosage Form
SOLUTION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CITRIC ACID MONOHYDRATE; POTASSIUM CITRATE; SODIUM CITRATEApproval Type
Unapproved
On Market Since
5/25/2005
Pharmacological Classes
Price Statistics
The NADAC for TRICITRATES ORAL SOLUTION has been published 423 times since Nov 28, 2013, and over the history we have for it it has risen 57.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0314 per ML |
|---|---|
| All-time high | $0.0437 (Jun 6, 2018) |
| All-time low | $0.0189 (Jan 22, 2014) |
| 52-week high | $0.0364 |
| 52-week low | $0.0298 |
| Median price | $0.0323 |
| Average price | $0.0316 |
| Largest weekly change | +64.7% (Mar 21, 2018) |
| Weeks tracked | 423 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the POTASSIUM CITRATE, SODIUM CITRATE, and CITRIC ACID MONOHYDRATE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
PAI Holdings LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
POTASSIUM CITRATE, SODIUM CITRATE, and CITRIC ACID MONOHYDRATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-coagulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRICITRATES ORAL SOLUTION?
The current National Average Drug Acquisition Cost (NADAC) for TRICITRATES ORAL SOLUTION, manufactured by PAI Holdings LLC, is $0.0314 per ML (NDC 00121067716), effective Sep 30, 2026.
How has the price of TRICITRATES ORAL SOLUTION changed over time?
Over the history we have for it, the NADAC for TRICITRATES ORAL SOLUTION has risen 57.1%. It has been tracked across 423 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TRICITRATES ORAL SOLUTION?
Since Nov 28, 2013, the NADAC for TRICITRATES ORAL SOLUTION has ranged from a low of $0.0189 (Jan 22, 2014) to a high of $0.0437 (Jun 6, 2018), with a median of $0.0323 per ML.
Are there cheaper alternatives to TRICITRATES ORAL SOLUTION?
No other NADAC-published product currently shares the active ingredient and strength of TRICITRATES ORAL SOLUTION in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TRICITRATES ORAL SOLUTION?
TRICITRATES ORAL SOLUTION (NDC 00121067716) is labeled by PAI Holdings LLC, and CMS classifies it as a generic product.